OBJECTIVES: Identify a population of MS patients new to treatment with natali- zumab. Observe and record healthcare utilization before initiation of natalizumab and up to 1 year after continuing treatment. Compare and quantify differences in healthcare utilization for the period prior to natalizumab treatment through the following calendar year. METHODS: Using integrated medical and pharmacy claims data (IMS LifeLinkTM Health Plan Claims and Longitudinal Prescriptions databases), patients were included in the analysis based on the presence of a diagnosis of MS (ICD-9 code 340.*) during calendar years 2006 through 2008. Clinical and utilization information related to the treatment ofMS were captured using the Episode Treatment GroupTM (ETGTM) episode-buildingsoftware. RESULTS: From the database, 349 MS patients that were both new to natalizumab treatment in 2007 and had 3 full calendar years of data were observed. In the year of treatment initiation with natalizumab, there was an overall increase in the number ofprescriptions received (14.0 to 22.6 per year), as well outpatient medical services (16.1 to 25.6) which would be expected with starting a new MS therapy. In addition to these increases, ER and inpatient utilization were also on the rise prior to initiation of natalizumab, however, utilization of ER and inpatient services significantly decreased in the following calendar year. During this period, there were also significant decreases in the amount ofdrugs used for supportive care ofMS includingcorticosteroids, antispas- tic agents, and benzodiazepines. CONCLUSIONS: Healthcare costs were at their highest in the year natalizumab was initiated. Following initiation of natalizumab therapy, there was a decrease in ER, inpatient and supportive care utilization.
Pill, M., & Gilkin, B. (2011). PND26 MEASURING THE IMPACT OF NATALIZUMAB THERAPY ON HEALTH CARE UTILIZATION IN A COMMERCIALY MANAGED MULTIPLE SCLEROSIS POPULATION. Value in Health, 14(3), A206. https://doi.org/10.1016/j.jval.2011.02.1136